達安基因(002030.SZ):子公司丙型肝炎病毒抗體(HCV)對照品取得醫療器械註冊證
格隆匯6月24日丨達安基因(002030.SZ)公佈,近日,公司下屬控股子公司廣州市達瑞生物技術股份有限公司取得國家藥品監督管理局頒發的醫療器械註冊證一個,具體為:醫療器械名稱:丙型肝炎病毒抗體(HCV)對照品,註冊證編號:國械注準20243401117。有效期自批准之日起至2029年6月17日。預期用途:用於檢測丙型肝炎病毒抗體定性項目的臨界值校正。目前,公司控股子公司廣州市達瑞生物技術股份有限公司已獲得"丙型肝炎病毒抗體(HCV)對照品"的醫療器械註冊證,上述產品尚處於市場開發階段,市場需求存在不確定性,敬請投資者注意風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.